NEW YORK, NY 10010, US
There are serious deficits in current melanoma therapy. There are no effective treatments for melanoma that has spread to the brain. Many patients either do not respond to currently approved melanoma therapies or rapidly acquire drug resistance and fail treatment. Approved immunologic therapies cause severe auto-immune complications that are sometimes fatal.
ENB Therapeutics wants to fill the gaps in current melanoma therapy. We are developing small molecule inhibitors of a novel target that is a master regulator of melanoma progression. In preclinical trials, our therapies show efficacy in treating melanoma that has spread to the brain. They bypass mechanisms of drug resistance to allow for treatment of patients with treatment failure on approved medications. They target the immune system specifically to the melanoma cell so our anticipated side-effect profile is low. We have developed a companion diagnostic to help determine those most likely to respond to our therapies and this will appeal to insurance carriers. This diagnostic test predicts that the majority of melanoma patients will respond to our therapies.
Please help us to bring these treatments to those in need.
Products / Services
ENB Therapeutics is developing small molecule inhibitors of a novel pathway to treat melanoma. ENB001 is the first drug in our pipeline and has shown efficacy in preclinical studies for melanoma. We are currently seeking funds for to develop a slow release formulation of this therapeutic agent.
There are currently no approved treatments for brain involvement of melanoma. ENB001B is a a variant of ENB001A that has been modified so that it can cross the blood brain barrier and treat melanoma metastases to brain. We are currently seeking funds to develop this formulation.
Sumayah Jamal, MD-PhD
Sumayah Jamal, MD-PhD, Co-founder, Chief Scientific Officer.
Clinical Assistant Prof. of Dermatology, NYUMC.
Research Assist. Professor of Microbiology, NYUMC.
• 20+ years experience in research, trained under Nobel laureate Richard Axel.
• Published pivotal studies as a PI on the role of the Endothelin B receptor in melanoma progression.
• Recipient of the American Academy of Dermatology Young Investigator Award, the American Academy of Dermatology Everett C. Fox M.D. Award, and the Pan American Society for Pigment Cell Research Young Investigator Award.
Dr. Jamal is currently recruiting for the positions of CEO and CFO.
Robert Schneider, PhD
Robert Schneider, PhD, Co-founder, Chair of Scientific Advisory Board
Associate Dean, Office of Therapeutics Alliances, NYUMC, Associate Director for Translational Research, NYU Cancer Institute, Director, Breast Cancer Program
Senior PI, Oversees Drug Discovery and Development programs at NYUMC,
Strong track record of licensing inventions and intellectual property to industry and investment partners
Co-founder of numerous biopharma start up companies including ImClone, Canji and PTC Therapeutics.
Iman Osman, MD
Iman Osman, MD, Scientific Advisory Board
Professor, Departments of Dermatology, Medicine and Urology
Associate Director, NYU Cancer Institute
Director, Interdisciplinary Melanoma Program NYUMC
Oversees melanoma clinical trials at NYUMC
Anthony Davenport, PhD
Anthony Davenport, PhD, Scientific Advisory Board
Professor, Departments of Cardiovascular Pharmacology, Cambridge University
Director, British Heart Foundation Human Receptor Group
One of the foremost experts in Endothelin receptor antagonist pharmacology.
Extensively published: More than 100 peer reviewed publications and books in prestigious journals
Acting/Interim Executive Officer
Acting Chief Business Officer
Managing Director of Kema Partners, LLC
20 years’ experience in the finance and life sciences sectors, advising government, public and private Institutions, and emerging companies from around the globe
Demonstrated success in identifying undervalued opportunities and unlocking value for both partners and clients and has advised over 100 public and private companies,
Founder of Trout Capital LLC, a world leader in strategic investor relations
Consulting Business Development
George Naumov, PhD
Management Consultant MedPharma Partners; Chair, Life Sciences Screening Committee, Boston Harbor Angels; Voting member, Investors Collaborative.
Advisory services to VC portfolio companies.
Worked as Associate Principal Scientist, In Vivo Pharmacology-Oncology at Merck.
Scouted early-stage life-science business opportunities for potential investment/licensing/M&A by Merck & Co. and the Merck Venture Fund.
• Established a deal flow between Merck and the Boston Angel community, with primary focus on Boston Harbor Angels.